UK appeals court upholds Genentech patent


England’s Court of Appeal has affirmed a 2012 High Court ruling that pharmaceutical company Genentech’s patent covering human vascular endothelial growth factor (hVEGF) antagonists is valid and has been infringed by Regeneron and Bayer Pharmaceutical’s drug Eylea.

Genentech, hVEGF, Regeneron, Bayer, Trap Eye, patent, Court of Appeal